Node PositivePrognostic and Predictive Information for Node-Positive Patients

I believe that no matter how many lymph
nodes are involved, if you are not going to
benefit from chemotherapy, you’re not
going to benefit.”

           -Dr. Christy Russell, Associate Professor
            of Clinical Oncology and Co-Director,
            University of Southern California Norris
            Lee Breast Center

PrognosticPrognostic for Node-Positive Patients

The Oncotype DX® Breast Recurrence Score™ result provides important prognostic information about the estimated risk of distant recurrence for node-positive patients result provides important prognostic information about the estimated risk of distant recurrence for node-positive patients1

TransATAC

TransATAC: Prospective analysis of archived tissue from 1,231 postmenopausal patients with invasive breast cancer treated with tamoxifen or an aromatase inhibitor, of whom 1,178 were estrogen receptor (ER) positive and either node negative or node positive. Of 306 node-positive patients, 79% had 1 to 3 positive nodes, 21% had ≥ 4 positive nodes, and 4% had unknown nodal status. The mean age was 64 years, and 67% of tumors were ≤ 2.0 cm in size.1

PredictivePredictive for Node-Positive Patients

Only the Breast Recurrence Score predicts the magnitude of chemotherapy benefit for node-positive patients2

SWOG 8814

SWOG 8814: Prospective analysis of archived tissue from 367 postmenopausal, hormone receptor (HR)–positive, node-positive patients with invasive breast cancer treated with tamoxifen or tamoxifen plus CAF. Approximately 62% had 1 to 3 positive nodes, and the remainder had ≥ 4. Mean age was 60 years (range 42–81), 20% were progesterone receptor (PR)–negative, and 64% of tumors were 2 cm to 5 cm in size.2

The Breast Recurrence Score predicts the magnitude of chemotherapy benefit across the range of Recurrence Score results, with higher scores corresponding to a greater benefit.

 

“Oncotype DX was done on our stored specimens of node-positive disease, and what we found was almost a duplication of what the node-negative disease trial B-20 found—that the assay was prognostic and it was predictive.”

                          – Kathy S. Albain, MD, FACP, Director, Breast Clinical Research Program; Co-Director,
                             Breast Oncology Center; Director, Thoracic Oncology Program; Professor of Medicine,
                             Stritch School of Medicine, Loyola University Chicago

 


Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Kathy Albain of the Loyola University Medical Center to discuss managing breast cancer patients with node positive ER+ disease with the Breast Recurrence Score.

 

REFERENCES
1. Dowsett et al. J Clin Oncol. 2010.
2. Albain et al. Lancet Oncol. 2010.

 

Next: The Intermediate Breast Recurrence Score Result